Trial · NCT00032487
Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
NCT00032487, Phase 3, Completed, VA Office of Research and Development; results first posted 2014-02-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT). Trials, record NCT00032487. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00032487
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
- NCT number
- NCT00032487
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 1,791 participants, actual
- Lead sponsor
- VA Office of Research and Development
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Insulin, Glimepiride, Rosiglitazone, Metformin
- First posted
- 2002-03-22
- Last updated
- 2017-03-30
- Results first posted
- 2014-02-12
- Limitations and caveats
Our study had several limitations. Since we were studying veterans, the patients were predominantly men, and extrapolation of our findings to women must be done with caution.Changes in therapeutic agents have occurred since the design of our protocol
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Primary Major Macrovascular Events | Post baseline time to the first major macrovascular event up to 82 months | Myocardial infarction (MI), intervention for coronary artery or Peripheral Vascular Disease (PVD), severe inoperable Coronary Artery Disease (CAD), new or worsening Congestive Heart Failure (CHF), stroke, Cardiovascular (CV) death, or amputation for ischemic gangrene. |
| Secondary | Secondary Endpoint | Post baseline time to first event up to 82 months | New or worsening angina, new transient ischemic attack (TIA), new intermittent claudication or critical limb ischemia with Doppler evidence or total mortality. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Primary Major Macrovascular Events | Post baseline time to the first major macrovascular event up to 82 months | participants | NUMBER | |
| SECONDARY | Secondary Endpoint | Post baseline time to first event up to 82 months | participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Primary Major Macrovascular Events | Arm 1 | 264 | participants | ||
| Primary Major Macrovascular Events | Arm 2 | 235 | participants | ||
| Secondary Endpoint | Arm 1 | 283 | participants | ||
| Secondary Endpoint | Arm 2 | 312 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Standard Glycemic Control | 899 | |
| Overall Study | STARTED | Intensive Glycemic Control | 892 | |
| Overall Study | COMPLETED | Standard Glycemic Control | 760 | |
| Overall Study | COMPLETED | Intensive Glycemic Control | 772 | |
| Overall Study | NOT COMPLETED | Standard Glycemic Control | 139 | |
| Overall Study | NOT COMPLETED | Intensive Glycemic Control | 120 |
Source ClinicalTrials.gov
Adverse events86
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Musculoskeletal | Musculoskeletal and connective tissue disorders | Arm 1 | 493 | 899 | 493 |
| other | Musculoskeletal | Musculoskeletal and connective tissue disorders | Arm 2 | 480 | 892 | 480 |
| other | Infections | Infections and infestations | Arm 1 | 385 | 899 | 385 |
| other | Infections | Infections and infestations | Arm 2 | 354 | 892 | 354 |
| other | General Disorders | General disorders | Arm 1 | 315 | 899 | 315 |
| other | General Disorders | General disorders | Arm 2 | 290 | 892 | 290 |
| other | Nervous system | Nervous system disorders | Arm 1 | 318 | 899 | 318 |
| other | Nervous system | Nervous system disorders | Arm 2 | 283 | 892 | 283 |
| other | Gastrointestinal Disorders | Gastrointestinal disorders | Arm 1 | 288 | 899 | 288 |
| other | Gastrointestinal Disorders | Gastrointestinal disorders | Arm 2 | 289 | 892 | 289 |
1 to 10 of 86Source ClinicalTrials.gov
See all 86 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm 1 | ||
| Total, all-cause mortality | Arm 2 | ||
| Total, other adverse events | Arm 1 | 730 | 899 |
| Total, other adverse events | Arm 2 | 675 | 892 |
| Total, serious adverse events | Arm 1 | 144 | 899 |
| Total, serious adverse events | Arm 2 | 197 | 892 |
Source ClinicalTrials.gov
Papers25
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Arm 1 vs Arm 2: Secondary Endpoint | Trial comparisons |
| Arm 1 vs Arm 2: Primary Major Macrovascular Events | Trial comparisons |
| Arm 1 vs Arm 2: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00032487
GET https://conductscience.org/api/trials/v1/NCT00032487/events?page=2